Top Markets
Coin of the day
20/20 Biolabs Inc. 20/20 Biolabs Inc.

20/20 Biolabs Inc.

AIDX
Rank in Stocks #33864
20/20 GeneSystems, Inc. operates as a clinical laboratory testing company... 20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offers viral testing services such as rapid COVID-19 test kits, including the Assure COVID-19 IgG/IgM rapid test. It operates the Clinical Lab Innovation Axcelerator (CLIAx), a shared laboratory facility that supports diagnostic test developers in bringing products to the U.S. market. The company also delivers its cancer screening algorithm technology through a software as a service (SaaS) platform in partnership with healthcare providers and supports diagnostic startups by offering access to shared laboratory space and resources. The company was founded in 2000 and is based in Gaithersburg, Maryland.
Share Price
$0.5475
Last synced: 2026-08-14
Market Cap
$6.71M
Change (1 day)
5.57%
Change (1 year)
-
Country
US
Trade 20/20 Biolabs Inc. (AIDX)

Category

Revenue for 20/20 Biolabs Inc. (AIDX)
Revenue in Aug 2026 TTM: 0
According to 20/20 Biolabs Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for 20/20 Biolabs Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors